The utility of serology for elimination surveillance of trachoma

Pinsent, Amy; Solomon, Anthony W.; Bailey, Robin L.; Bid, Rhiannon; Cama, Anaseini; Dean, Deborah; Goodhew, Brook; Gwyn, Sarah E.; Jack, Kelvin R.; Kandel, Ram Prasad; Kama, Mike; Massae, Patrick; Macleod, Colin; Mabey, David C. W.; Migchelsen, Stephanie; Müller, Andreas; Sandi, Frank; Sokana, Oliver; Taoaba, Raebwebwe; Tekeraoi, Rabebe; Martin, Diana L.; White, Michael. T.

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

The utility of serology for elimination surveillance of trachoma

Published Date:

December 21 2018

Source:

Nat Commun. 9

Language:

English

[PDF-1.00 MB]

Details:

Personal Authors:

Pinsent, Amy ; Solomon, Anthony W. ; Bailey, Robin L. ; Bid, Rhiannon ; Cama, Anaseini ; ... More ▼

Keywords:

[+]

Pubmed ID:

30575720

Pubmed Central ID:

PMC6303365

Description:

Robust surveillance methods are needed for trachoma control and recrudescence monitoring, but existing methods have limitations. Here, we analyse data from nine trachoma-endemic populations and provide operational thresholds for interpretation of serological data in low-transmission and post-elimination settings. Analyses with sero-catalytic and antibody acquisition models provide insights into transmission history within each population. To accurately estimate sero-conversion rates (SCR) for trachoma in populations with high-seroprevalence in adults, the model accounts for secondary exposure to Chlamydia trachomatis due to urogenital infection. We estimate the population half-life of sero-reversion for anti-Pgp3 antibodies to be 26 (95% credible interval (CrI): 21-34) years. We show SCRs below 0.015 (95% confidence interval (CI): 0.0-0.049) per year correspond to a prevalence of trachomatous inflammation-follicular below 5%, the current threshold for elimination of active trachoma as a public health problem. As global trachoma prevalence declines, we may need cross-sectional serological survey data to inform programmatic decisions.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

001/World Health Organization/International

Main Document Checksum:

[+]

Supporting Files:

	41467_2018_7852_MOESM1_ESM.pdf	application/pdf
	41467_2018_7852_MOESM2_ESM.pdf	application/pdf
	41467_2018_Article_7852.nxml	text/xml
	41467_2018_7852_Fig1_HTML.gif	image/gif
	41467_2018_7852_Fig1_HTML.jpg	image/jpeg
	41467_2018_7852_Fig2_HTML.gif	image/gif
	41467_2018_7852_Fig2_HTML.jpg	image/jpeg
	41467_2018_7852_Fig3_HTML.gif	image/gif
	41467_2018_7852_Fig3_HTML.jpg	image/jpeg
	41467_2018_7852_Fig4_HTML.gif	image/gif
	41467_2018_7852_Fig4_HTML.jpg	image/jpeg

No Related Documents.

You May Also Like:

Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration

Personal Author:

Goodhew, Erica Brook; Morgan, Sheri Maria G; Switzer, Andrew J; Munoz, Beatriz; Dize, Laura; Gaydos, Charlotte; Mkocha, Harran; West, Sheila K; Wiegand, Ryan E; Lammie, Patrick J; Martin, Diana L;

Published:

Apr 22 2014

Source:

BMC Infect Dis. 2014; 14:216.

Description:

Background : Blinding trachoma, caused by the bacteria Chlamydia trachomatis, is a neglected tropical disease targeted for elimination by 2020. A major component of the elimination strategy is mass drug administration (MDA) with azithromycin. Current...

File Type:

[PDF - 562.06 KB]
Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger

Personal Author:

Kim, Jessica S.; Oldenburg, Catherine E.; Cooley, Gretchen; Amza, Abdou; Kadri, Boubacar; Nassirou, Baido; Cotter, Sun Yu; Stoller, Nicole E.; West, Sheila K.; Bailey, Robin L.; Keenan, Jeremy D.; Gaynor, Bruce D.; Porco, Travis C.; Lietman, Thomas M.; Martin, Diana L.;

Published:

January 28 2019

Source:

PLoS Negl Trop Dis. 13(1)

Description:

Background : Program decision-making for trachoma elimination currently relies on conjunctival clinical signs. Antibody tests may provide additional information on the epidemiology of trachoma, particularly in regions where it is disappearing or elim...

File Type:

[PDF - 683.49 KB]
Serological Measures of Trachoma Transmission Intensity

Personal Author:

Martin, Diana L.; Wiegand, Ryan; Goodhew, Brook; Lammie, Patrick; Black, Carolyn M.; West, Sheila; Gaydos, Charlotte A.; Dize, Laura; Mkocha, Harran; Kasubi, Mabula; Gambhir, Manoj;

Published:

Dec 21 2015

Source:

Sci Rep. 2015; 5.

Description:

Ocular infection with Chlamydia trachomatis can lead to trachoma, a leading infectious cause of blindness. Trachoma is targeted for elimination by 2020. Clinical grading for ocular disease is currently used for evaluating trachoma elimination program...

File Type:

[PDF - 424.14 KB]
Trachoma and Yaws: Common Ground?

Personal Author:

Solomon, Anthony W.; Marks, Michael; Martin, Diana L.; Mikhailov, Alexei; Flueckiger, Rebecca M.; Mitjà, Oriol; Asiedu, Kingsley; Jannin, Jean; Engels, Dirk; Mabey, David C. W.;

Published:

Dec 03 2015

Source:

PLoS Negl Trop Dis. 9(12).

File Type:

[PDF - 1.93 MB]
Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma Program

Personal Author:

Pant, Bidya Prasad; Bhatta, Ramesh C.; Chaudhary, J. S. P.; Awasthi, Suresh; Mishra, Sailesh; Sharma, Shekhar; Cuddapah, Puja A.; Gwyn, Sarah E.; Stoller, Nicole E.; Martin, Diana L.; Keenan, Jeremy D.; Lietman, Thomas M.; Gaynor, Bruce D.;

Published:

Feb 12 2016

Source:

PLoS Negl Trop Dis. 10(2).

Description:

Background : The WHO seeks to control trachoma as a public health problem in endemic areas. Achham District in western Nepal was found to have TF (trachoma follicular) above 20% in a 2006 government survey, triggering 3 annual mass drug administratio...

File Type:

[PDF - 280.06 KB]